The treatment of multiple myeloma with docetaxel (an ECOG study)

Leukemia Research

Volumn 27, Issue 8, 2003, Pages 751-754

  Friedenberg, William R ^a   Graham, David ^b   Greipp, Philip ^c   Blood, Emily ^d   Winston, Robert D ^e  

^a GUTHRIE RESEARCH INSTITUTE   (United States)

^b Carle Clinic   (United States)

^c MAYO CLINIC   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e North Memorial Humphrey Cancer Center   (United States)

Author keywords

Docetaxel; Multiple myeloma; Refractory myeloma; Relapsing myeloma

Indexed keywords

DOCETAXEL;

ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CYTOTOXICITY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOPENIA; MALE; METABOLIC DISORDER; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 0037528729     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00344-2     Document Type: Article

References (9)

1. Cerny T., Kaplan S., Pavlidis N.et al. Docetaxel (Taxotere) is active in non-small cell lung cancer: a phase II trial of EORTC early clinical trials group (ECTG). Br. J. Cancer. 70:1994;384-387.
2. ten Bokkel Huinink W.W., Prove A.M., Piccart M.et al. A phase II trial of docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann. Oncol. 5:1994;527-532.
3. Cortes J.E., Pazdur R. Docetaxel. J. Clin. Oncol. 13:1995;2643-2655.
4. Roy S.N., Horwitz S.B. A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res. 45:1985;3856-3863.
5. Gupta R.S. Taxol resistant mutants of Chinese hamster ovary cells: genetic biochemical, and cross-resistant studies. J. Cell. Physiol. 114:1983;137-144.
6. Dimopoulos M.A., Arbuck S., Huber M.et al. Primary therapy of multiple myeloma with paclitaxel (Taxol). Ann. Oncol. 5:1994;757-759.
7. Miller H., Leong T., Khandekar J.et al. Paclitaxel as the initial treatment of multiple myeloma (MM) an Eastern Cooperative Oncology Group (ECOG) study. Am. J. Clin. Oncol. (CCT). 21(6):1998;553-556.
8. Atkinson E.N., Brown B.W. Confidence limits for probability of response in multistage phase II clinical trials. Biometrics. 41:1985;741-744.
9. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.